Breaking News

Novartis Recalls Sandimmune, Neoral Blister Packs Due to Packaging Failure

Corrective action plan to address blister packs that do not meet U.S. child-resistant packaging requirements, there are no quality or efficacy issues.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Novartis announced a Consumer Product Safety Commission (CPSC)-approved corrective action plan after identifying certain blister card packages (blister packs) of SANDIMMUNE (cyclosporine capsules, USP) 100-mg soft gelatin capsules and NEORAL (cyclosporine capsules, USP) MODIFIED 100-mg soft gelatin capsules distributed in the U.S. do not meet child-resistant packaging requirements, posing a potential risk of harm. Novartis notified the CPSC and the FDA and is working closely with the CPSC to ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters